New report shows growing number of cancer cases across the globe to foster the growth of liquid biopsy market


The global liquid biopsy market is segmented into biomarkers such as circulating tumor cells (CTCs), extracellular vesicles (Exosomes) and cell-free circulating DNA (cfDNA). Among these segments, circulating tumor cells (CTCs) segment is expected to occupy top position in overall liquid biopsy market during the forecast period. Further, ability to detect the cancer outcome predictions through prognostic scoring is driving the growth of the circulating tumor cells (CTCs) segment. Furthermore, advancements by the manufacturing companies such as development of high end systems are envisioned to bolster the growth of circulating tumor cells market during the forecast period.

Global liquid biopsy market is expected to flourish at a CAGR of 25.0% over the forecast period. Moreover, the global liquid biopsy market is anticipated to garner USD 10,850 Million by the end of 2021. Factors such as increasing penetration of cancer, rising awareness regarding the detection of cancer, increasing healthcare expenditure are anticipated to be the dynamic factor behind the growth of liquid biopsy market.

North America dominated the overall market of liquid biopsy in 2016. Further, North America is projected to continue its dominance over the forecast period owing to the rising incidences of cancer in the region. Moreover, rising spending on cancer care is expected to positively impact the growth of the liquid biopsy market. Asia Pacific liquid biopsy market is anticipated to witness robust growth during the forecast period. Factors such as increasing medical tourism, rising number of specialty hospitals are anticipated to garner the growth of liquid biopsy market in the Asia Pacific region…

Read more at Medgadget

Leave a Reply

Your email address will not be published. Required fields are marked *